DR10624 Injection

DRUG3 trials

Sponsors

Zhejiang Doer Biologics Co., Ltd.

Conditions

HypertriglyceridemiaMASLDSevere HypertriglyceridemiaSevere Hypertriglyceridemia (sHTG)

Phase 2

A Phase II Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia

CompletedNCT06555640

Zhejiang Doer Biologics Co., Ltd.Severe Hypertriglyceridemia

Start: 2024-08-01End: 2025-08-29Updated: 2026-01-13

Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects

Active, not recruitingNCT07024212

Zhejiang Doer Biologics Co., Ltd.MASLD

Start: 2025-04-22End: 2026-09-30Target: 110Updated: 2026-07-07

Phase 3

A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia

Not yet recruitingNCT07693777

Zhejiang Doer Biologics Co., Ltd.Hypertriglyceridemia, Severe Hypertriglyceridemia (sHTG)

Start: 2026-08-17End: 2029-12-05Target: 480Updated: 2026-07-10